Teva Pharmaceutical Industries (TEVJF) Debt Ratio (2009 - 2026)

Teva Pharmaceutical Industries has disclosed Debt Ratio across 18 years of filings, most recently posting 0.42 for Q1 2026.

• Quarterly Debt Ratio fell 4.2% year-over-year to 0.42 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 0.42 (down 4.2% YoY) and the FY2025 annual result came in at 0.41, down 8.79% from the prior year.
• Debt Ratio rose to 0.42 in Q1 2026, from 0.41 in the prior quarter.
• Over five years, Debt Ratio peaked at 0.49 in Q1 2022 and troughed at 0.41 in Q4 2025.
• A 5-year average of 0.46 and a median of 0.46 in 2023 frame the typical range for Debt Ratio.
• Annual changes were most pronounced in 2023 — Debt Ratio decreased 0.21% — and 2025, when it fell 8.79%.
• Tracing TEVJF's Debt Ratio over 5 years: stood at 0.48 in 2022, then dropped by 5.36% to 0.46 in 2023, then retreated by 0.87% to 0.45 in 2024, then declined by 8.79% to 0.41 in 2025, then rose by 0.68% to 0.42 in 2026.
• Business Quant data shows TEVJF's Debt Ratio at 0.42 in Q1 2026, 0.41 in Q4 2025, and 0.42 in Q3 2025.